Alassar Aiman, Roy David, Valencia Oswaldo, Brecker Stephen, Jahangiri Marjan
From the *Department of Cardiac Surgery, and †Department of Cardiology, St. George's Hospital, London, UK.
Innovations (Phila). 2013 Sep-Oct;8(5):359-63. doi: 10.1097/IMI.0000000000000024.
Transcatheter aortic valve implantation (TAVI) is considered the standard of care for patients with severe symptomatic aortic stenosis unsuitable for surgery. However, short- and long-term mortality after TAVI are still relatively high. The aim of this study was to establish survival, predictive factors, and causes of mortality after TAVI at early and midterm follow-up.
Between December 2007 and May 2012, a total of 119 patients with symptomatic severe aortic stenosis underwent 121 TAVI procedures. The mean ± SD age was 81 ± 9 years, and 59% were men. The mean ± SD logistic European System for Cardiac Operative Risk Evaluation was 22 ± 15. Seventy-five patients (63%) were in New York Heart Association functional class III to IV. The transfemoral approach was used in 76% of the patients. One hundred ten patients (91%) had the CoreValve prosthesis, and 11 (9%) had an Edwards SAPIEN valve. Baseline characteristics, procedural complications, and outcomes were collected prospectively. Clinical outcomes were defined according to the Valve Academic Research Consortium criteria. Follow-up was completed for 100% of the patients at a median of 1.3 years (range, 0-4.5).
The total number of deaths was 36 (30%). One-month mortality was 4.2%. Actuarial survival was 83.2%, 76.5%, and 68.2% at 1, 2, and 3 years, respectively. Acute kidney injury occurred in 12.3% of the patients, none of whom required dialysis during hospitalization. Twenty-one patients (17.6%) had new conduction abnormalities that required permanent pacemaker implantation before hospital discharge. The incidence of major vascular injury and stroke was 2.4% and 4.1%, respectively. Survival was significantly adversely affected by preprocedural left ventricular dysfunction (P = 0.04), history of atrial fibrillation (P = 0.03), prior heart block (P < 0.01), and critical preoperative state (P < 0.01). Twelve (33%) of the 36 deaths were due to bronchopneumonia. In 12 (33%) of the 36 patients who died, mortality was related to cardiac causes. When a death occurred within the first 30 days, it was mainly cardiac in nature (80%). Twelve patients (34%) died because of a variety of other reasons such as pulmonary embolism, stroke, cancer, renal failure, and sepsis.
Preprocedural left ventricular dysfunction, atrial fibrillation, and heart block are independent predictive factors of all-cause mortality. Early mortality was mainly cardiac in origin. Most of the late deaths were caused by noncardiac reasons, with bronchopneumonia being reported as the most common cause of late mortality.
经导管主动脉瓣植入术(TAVI)被认为是不适于手术治疗的重度有症状主动脉瓣狭窄患者的标准治疗方法。然而,TAVI术后的短期和长期死亡率仍然相对较高。本研究的目的是确定TAVI术后早期和中期随访的生存率、预测因素及死亡原因。
2007年12月至2012年5月期间,共有119例有症状的重度主动脉瓣狭窄患者接受了121例TAVI手术。平均年龄±标准差为81±9岁,男性占59%。平均±标准差的逻辑欧洲心脏手术风险评估系统评分为22±15。75例患者(63%)处于纽约心脏协会心功能Ⅲ至Ⅳ级。76%的患者采用经股动脉途径。110例患者(91%)植入了CoreValve瓣膜,11例(9%)植入了爱德华SAPIEN瓣膜。前瞻性收集基线特征、手术并发症及结果。临床结果根据瓣膜学术研究联盟标准定义。100%的患者完成随访,中位随访时间为1.3年(范围0 - 4.5年)。
死亡总数为36例(30%)。1个月死亡率为4.2%。1年、2年和3年的精算生存率分别为83.2%、76.5%和68.2%。12.3%的患者发生急性肾损伤,住院期间均无需透析。21例患者(17.6%)出现新的传导异常,在出院前需要植入永久性起搏器。主要血管损伤和卒中的发生率分别为2.4%和4.1%。术前左心室功能障碍(P = 0.04)、心房颤动病史(P = 0.03)、既往心脏传导阻滞(P < 0.01)及术前危急状态(P < 0.01)对生存率有显著不利影响。36例死亡患者中有12例(33%)死于支气管肺炎。36例死亡患者中有12例(33%)的死亡与心脏原因有关。死亡发生在术后30天内时,主要为心脏原因(80%)。12例患者(34%)因肺栓塞、卒中、癌症、肾衰竭和脓毒症等多种其他原因死亡。
术前左心室功能障碍、心房颤动和心脏传导阻滞是全因死亡率的独立预测因素。早期死亡主要源于心脏原因。大多数晚期死亡由非心脏原因引起,支气管肺炎被报告为晚期死亡的最常见原因。